News
Prescient (ASX: PTX) shares jump 6% on new US patent
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key US Patent for its OmniCAR portfolio “SpyCatcher and SpyTag: Universal…
News
Prescient Therapeutics delivers new clinic-ready cell therapy technology
Prescient Therapeutics Ltd (ASX:PTX)’s Steven Yatomi-Clarke outlines the company’s oncology treatment vision in a new interview with Proactive. The healthcare stock adopts a portfolio approach when…
News
Prescient (ASX: PTX) rolls out new cell therapy platform, CellPryme-M
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell therapy platform, “CellPryme-M”. It is a high-performance cell therapy manufacturing…
News
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy sector, unveiling its latest platform to advance CAR-T therapy globally….
Article, News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with the Peter MacCallum Cancer Centre.
Article, News
Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance…
Article, News
Prescient Therapeutics (ASX:PTX) unveils new cell therapy platform
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M. CellPryme-M is a platform technology that produces superior cells during the cell…
News
Prescient Therapeutics Are Developing Game-Changing Cancer Treatments
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor to discuss the company’s innovative cancer treatments with the Biotech…
News
Prescient (ASX: PTX) expands its PTX-200 trial in AML patients
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing its study of diseases of unmet medical needs. PTX will…
News
Cell therapies progress and strong cash position mark Prescient’s March quarter
Prescient Therapeutics (ASX: PTX) signed off the March quarter with major progress made in its Cell Therapy Enhancements and OmniCAR program. The clinical-stage oncology company made…